novo nordisk glp-1 products promotes new receptor agonist to fight diabetes, obesity < Pharma < Article Novo inks Ascendis deal to

Saghazadeh S, Rinoldi C, Schot M, Kashaf SS, Sharifi F, Jalilian E, Nuutila K, Giatsidis G, Mostafalu P, Derakhshandeh H, et al

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: A meta-analysis

You notice bleeding, itching, or new irritation after a bowel movement

Federal Trade Commission (FTC) investigators reported that PBMs inflated the prices of specialty generic drugs, including medications for heart disease and cancer, beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022

The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: a systematic review

Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project